Anaemia and iron deficiency in patients with rheumatoid arthritis and other chronic diseases^*

[1] Agrawal R., Kusek J.W., Pappas M.K.: A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int., 2015; 88: 905–914 AgrawalR. KusekJ.W. PappasM.K. A randomized trial of intravenous and oral iron in chronic kidney disease Kidney Int. 2015 88 905 914 10.1038/ki.2015.163458943626083656 Search in Google Scholar

[2] Alamanos Y., Drosos A.A.: Epidemiology of adult rheumatoid arthritis. Autoimmun. Rev., 2005; 4: 130–136 AlamanosY. DrososA.A. Epidemiology of adult rheumatoid arthritis Autoimmun. Rev. 2005 4 130 136 10.1016/j.autrev.2004.09.00215823498 Search in Google Scholar

[3] Albaramki J., Hodson E.M., Craig J.C., Webster A.C.: Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst. Rev., 2012; 1: CD007857 AlbaramkiJ. HodsonE.M. CraigJ.C. WebsterA.C. Parenteral versus oral iron therapy for adults and children with chronic kidney disease Cochrane Database Syst. Rev. 2012 1 CD007857 10.1002/14651858.CD007857 Search in Google Scholar

[4] Allen R.P., Auerbach S., Bahrain H., Auerbach M., Earley C.J.: The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. Am. J. Hematol., 2013; 88: 261–264 AllenR.P. AuerbachS. BahrainH. AuerbachM. EarleyC.J. The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia Am. J. Hematol. 2013 88 261 264 10.1002/ajh.2339723494945 Search in Google Scholar

[5] Anker S.D., Comin Colet J., Filippatos G., Wilenheimer R., Dickstein K., Drexler H., Lüscher T.F., Bart B., Banasiak W., Niegowska J., Kirwan B.A., Mori C.: Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Eng. J. Med., 2009; 361: 2436–2448 AnkerS.D. Comin ColetJ. FilippatosG. WilenheimerR. DicksteinK. DrexlerH. LüscherT.F. BartB. BanasiakW. NiegowskaJ. KirwanB.A. MoriC. Ferric carboxymaltose in patients with heart failure and iron deficiency N. Eng. J. Med. 2009 361 2436 2448 10.1056/NEJMoa090835519920054 Search in Google Scholar

[6] Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F. Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum., 1988; 31: 315–324 ArnettF.C. EdworthyS.M. BlochD.A. McShaneD.J. FriesJ.F. CooperN.S. HealeyL.A. KaplanS.R. LiangM.H. LuthraH.S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum. 1988 31 315 324 10.1002/art.17803103023358796 Search in Google Scholar

[7] Auerbach M., Adamson J.W.: How we diagnose and treat iron deficiency anemia. Am. J. Hematol., 2016; 91: 31–38 AuerbachM. AdamsonJ.W. How we diagnose and treat iron deficiency anemia Am. J. Hematol. 2016 91 31 38 10.1002/ajh.2420126408108 Search in Google Scholar

[8] Babitt J.L., Lin H.Y.: Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD. Am. J. Kidney Dis., 2010; 55: 726–741 BabittJ.L. LinH.Y. Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD Am. J. Kidney Dis. 2010 55 726 741 10.1053/j.ajkd.2009.12.030290503620189278 Search in Google Scholar

[9] Berner B., Akca D., Jung T., Muller G.A., Reuss-Borst M.A.: Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J. Rheumatol., 2000; 27: 1128–1135 BernerB. AkcaD. JungT. MullerG.A. Reuss-BorstM.A. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry J. Rheumatol. 2000 27 1128 1135 Search in Google Scholar

[10] Beutler E., Waalen J.: The definition of anemia: What is the lower limit of normal of the blood hemoglobin concentration? Blood, 2006; 107: 1747–1750 BeutlerE. WaalenJ. The definition of anemia: What is the lower limit of normal of the blood hemoglobin concentration? Blood 2006 107 1747 1750 10.1182/blood-2005-07-3046189569516189263 Search in Google Scholar

[11] Blanchette N.L., Manz D.H., Torti F.M., Torti S.V.: Modulation of hepcidin to treat iron deregulation: Potential clinical applications. Expert. Rev. Hematol., 2016; 9: 169–186 BlanchetteN.L. ManzD.H. TortiF.M. TortiS.V. Modulation of hepcidin to treat iron deregulation: Potential clinical applications Expert. Rev. Hematol. 2016 9 169 186 10.1586/17474086.2016.1124757484927226669208 Search in Google Scholar

[12] Bloxham E., Vagadia V., Scott K., Francis G., Saravanah V., Heycock C., Rynne M., Hamilton J., Kelly C.A.: Anaemia in rheumatoid arthritis: can we afford to ignore it? Postgrad. Med. J., 2011; 87: 596–600 BloxhamE. VagadiaV. ScottK. FrancisG. SaravanahV. HeycockC. RynneM. HamiltonJ. KellyC.A. Anaemia in rheumatoid arthritis: can we afford to ignore it? Postgrad. Med. J. 2011 87 596 600 10.1136/pgmj.2011.11750721659451 Search in Google Scholar

[13] Bogdanos D.P., Smyk D.S., Rigopoulou E.I., Mytylinaiou M.G., Heneghan M.A., Selmi C., Gershwin M.E.: Twin studies in autoimmune disease: Genetics, gender and environment. J. Autoimmun., 2012; 38: J156–J169 BogdanosD.P. SmykD.S. RigopoulouE.I. MytylinaiouM.G. HeneghanM.A. SelmiC. GershwinM.E. Twin studies in autoimmune disease: Genetics, gender and environment J. Autoimmun. 2012 38 J156 J169 10.1016/j.jaut.2011.11.00322177232 Search in Google Scholar

[14] Calisto Peres C., Leon R., Leon F., Ng S.L.: Rheumatoid arthritis and anemia: the impact of different anti-inflammatory therapies on hemoglobin levels. An observational study. Bol. Asoc. Med. P. R., 2012; 104: 34–41 Calisto PeresC. LeonR. LeonF. NgS.L. Rheumatoid arthritis and anemia: the impact of different anti-inflammatory therapies on hemoglobin levels. An observational study Bol. Asoc. Med. P. R. 2012 104 34 41 Search in Google Scholar

[15] Cappellini M.D., Comin-Colet J., de Francisco A., Dignass A., Doehner W., Lam C.S., Macdougall I.C., Rogler G., Camaschella C., Kadir R., Kassebaum N.J., Spahn D.R., Taher A.T., Musallam K.M.: Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am. J. Hematol., 2017; 92: 1068–1078 CappelliniM.D. Comin-ColetJ. de FranciscoA. DignassA. DoehnerW. LamC.S. MacdougallI.C. RoglerG. CamaschellaC. KadirR. KassebaumN.J. SpahnD.R. TaherA.T. MusallamK.M. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management Am. J. Hematol. 2017 92 1068 1078 10.1002/ajh.24820559996528612425 Search in Google Scholar

[16] Clark S.F.: Iron deficiency anemia: diagnosis and management. Curr. Opin. Gastroenterol., 2009; 25: 122–128 ClarkS.F. Iron deficiency anemia: diagnosis and management Curr. Opin. Gastroenterol. 2009 25 122 128 10.1097/MOG.0b013e32831ef1cd19262200 Search in Google Scholar

[17] Comin-Colet J., Lainscak M., Dickstein K., Filoppatos G.S., Johnson P., Lusher T.F., Mori C., Willenheimer R., Ponikowski P., Anker S.D.: The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: A subanalysis of the FAIR-HF study. Eur. Heart J., 2013; 34: 30–38 Comin-ColetJ. LainscakM. DicksteinK. FiloppatosG.S. JohnsonP. LusherT.F. MoriC. WillenheimerR. PonikowskiP. AnkerS.D. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: A subanalysis of the FAIR-HF study Eur. Heart J. 2013 34 30 38 10.1093/eurheartj/ehr504353391822297124 Search in Google Scholar

[18] Costenbader K.H., Chang S.C., DeVivo I., Plenge R., Karlson E.W.: Genetic polymorphisms in PTPN22, PADI-4, and CTLA-4 and risk for rheumatoid arthritis in two longitudinal cohort studies: Evidence of gene-environment interactions with heavy cigarette smoking. Arthritis Res. Ther., 2008; 10: R52 CostenbaderK.H. ChangS.C. DeVivoI. PlengeR. KarlsonE.W. Genetic polymorphisms in PTPN22, PADI-4, and CTLA-4 and risk for rheumatoid arthritis in two longitudinal cohort studies: Evidence of gene-environment interactions with heavy cigarette smoking Arthritis Res. Ther. 2008 10 R52 10.1186/ar2421248344118462498 Search in Google Scholar

[19] Daher R., Karim Z.: Iron metabolism: State of the art. Transfus. Clin. Biol., 2017; 24: 115–119 DaherR. KarimZ. Iron metabolism: State of the art Transfus. Clin. Biol. 2017 24 115 119 10.1016/j.tracli.2017.06.01528694024 Search in Google Scholar

[20] Demirag M.D., Haznedaroglu S., Sancak B., Konca C., Gulbahar O., Ozturk M.A., Goker B.: Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis. Intern. Med., 2009; 48: 421–426 DemiragM.D. HaznedarogluS. SancakB. KoncaC. GulbaharO. OzturkM.A. GokerB. Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis Intern. Med. 2009 48 421 426 10.2169/internalmedicine.48.157819293540 Search in Google Scholar

[21] De Falco L., Sanchez M., Silvestri L., Kannegiesser C., Muckenthaler M.U., Iolascon A., Gouya L., Camaschella C., Beaumont C.: Iron refractory iron deficiency anemia. Haematologica, 2013; 98: 845–853 De FalcoL. SanchezM. SilvestriL. KannegiesserC. MuckenthalerM.U. IolasconA. GouyaL. CamaschellaC. BeaumontC. Iron refractory iron deficiency anemia Haematologica 2013 98 845 853 10.3324/haematol.2012.075515366943823729726 Search in Google Scholar

[22] Di Giuseppe D., Discacciati A., Orsini N., Wolk A.: Cigarette smoking and risk of rheumatoid arthritis: A dose-response meta-analysis. Arthritis Res. Ther., 2014; 16: R61 Di GiuseppeD. DiscacciatiA. OrsiniN. WolkA. Cigarette smoking and risk of rheumatoid arthritis: A dose-response meta-analysis Arthritis Res. Ther. 2014 16 R61 10.1186/ar4498406037824594022 Search in Google Scholar

[23] Enjuanes C., Klip I.T., Brugera J., Cladellas M., Ponikowski P., Banasiak W., van Veldhuisen D.J., van der Meer P., Jankowska E.A., Comín-Colet J.: Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study. Int. J. Cardiol., 2014; 174: 268–275 EnjuanesC. KlipI.T. BrugeraJ. CladellasM. PonikowskiP. BanasiakW. van VeldhuisenD.J. van der MeerP. JankowskaE.A. Comín-ColetJ. Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study Int. J. Cardiol. 2014 174 268 275 10.1016/j.ijcard.2014.03.169 Search in Google Scholar

[24] Fernandez-Rodriguez A.M., Guindeo-Casasus M.C., Molero-Labarta T., Dominguez-Cabrera C., Hortal-Casc L., Perez-Borges P., Vega-Díaz N., Saavedra-Santana P., Palop-Cubillo L.: Diagnosis of iron deficiency in chronic renal failure. Am. J. Kidney Dis., 1999; 34: 508–513 Fernandez-RodriguezA.M. Guindeo-CasasusM.C. Molero-LabartaT. Dominguez-CabreraC. Hortal-CascL. Perez-BorgesP. Vega-DíazN. Saavedra-SantanaP. Palop-CubilloL. Diagnosis of iron deficiency in chronic renal failure Am. J. Kidney Dis. 1999 34 508 513 10.1016/S0272-6386(99)70079-X Search in Google Scholar

[25] Franchini M., Montagnana M., Lippi G.: Hepcidin and iron metabolism: From laboratory to clinical implications. Clin. Chim. Acta, 2010; 411: 1565–1569 FranchiniM. MontagnanaM. LippiG. Hepcidin and iron metabolism: From laboratory to clinical implications Clin. Chim. Acta 2010 411 1565 1569 10.1016/j.cca.2010.07.00320620132 Search in Google Scholar

[26] Fryc J., Sierakowski S.: Anaemia of chronic diseases in rheumatoid arthritis. Rheumatology, 2010; 48: 421–424 FrycJ. SierakowskiS. Anaemia of chronic diseases in rheumatoid arthritis Rheumatology 2010 48 421 424 Search in Google Scholar

[27] Glant T.T., Mikecz K., Rauch T.A.: Epigenetics in the pathogenesis of rheumatoid arthritis. BMC Med., 2014; 12: 35 GlantT.T. MikeczK. RauchT.A. Epigenetics in the pathogenesis of rheumatoid arthritis BMC Med. 2014 12 35 10.1186/1741-7015-12-35393681924568138 Search in Google Scholar

[28] Goodnough L.T., Maniatis A., Earnshaw P., Benoni G., Beris P., Bisbe E., Fergusson D.A, Gombotz H., Habler O., Monk T.G., Ozier Y., Slappendel R., Szpalski M.: Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br. J. Anaesth., 2011; 106: 13–22 GoodnoughL.T. ManiatisA. EarnshawP. BenoniG. BerisP. BisbeE. FergussonD.A. GombotzH. HablerO. MonkT.G. OzierY. SlappendelR. SzpalskiM. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines Br. J. Anaesth. 2011 106 13 22 10.1093/bja/aeq361300062921148637 Search in Google Scholar

[29] Goodnough L.T., Nemeth E., Ganz T.: Detection, evaluation, and management of iron-restricted erythropoiesis. Blood, 2010; 116: 4754–4761 GoodnoughL.T. NemethE. GanzT. Detection, evaluation, and management of iron-restricted erythropoiesis Blood 2010 116 4754 4761 10.1182/blood-2010-05-28626020826717 Search in Google Scholar

[30] Goodnough L.T., Schrier S.L.: Evaluation and management of anemia in the elderly. Am. J. Hematol., 2014; 89: 88–96 GoodnoughL.T. SchrierS.L. Evaluation and management of anemia in the elderly Am. J. Hematol. 2014 89 88 96 10.1002/ajh.23598428914424122955 Search in Google Scholar

[31] Hedge N., Rich M.W., Gayomali C.: The cardiomyopathy of iron deficiency. Tex. Heart Inst. J., 2006; 33: 340–344 HedgeN. RichM.W. GayomaliC. The cardiomyopathy of iron deficiency Tex. Heart Inst. J. 2006 33 340 344 Search in Google Scholar

[32] Jankowska E.A., Rozentryt P., Witkowska A., Nowak J., Hartmann O., Ponikowska B., Borodulin-Nadzieja L., Banasiak W., Polonski L., Filippatos G., McMurray J.J., Anker D., Ponikowski P.: Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur. Heart J., 2010; 31: 1872–1880 JankowskaE.A. RozentrytP. WitkowskaA. NowakJ. HartmannO. PonikowskaB. Borodulin-NadziejaL. BanasiakW. PolonskiL. FilippatosG. McMurrayJ.J. AnkerD. PonikowskiP. Iron deficiency: an ominous sign in patients with systolic chronic heart failure Eur. Heart J. 2010 31 1872 1880 10.1093/eurheartj/ehq15820570952 Search in Google Scholar

[33] Jankowska E.A., von Heahling S., Anker S.D., Macdougal I.C., Ponikowski P.: Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur. Heart J., 2013; 34: 816–829 JankowskaE.A. von HeahlingS. AnkerS.D. MacdougalI.C. PonikowskiP. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives Eur. Heart J. 2013 34 816 829 10.1093/eurheartj/ehs224359675923100285 Search in Google Scholar

[34] Jimenez K., Kulnigg-Dabsch S., Gasche C.: Management of iron deficiency anemia. Gastroenterol. Hepatol., 2015; 11: 241–250 JimenezK. Kulnigg-DabschS. GascheC. Management of iron deficiency anemia Gastroenterol. Hepatol. 2015 11 241 250 Search in Google Scholar

[35] Jones G., Sebba A., Gu J., Lowenstein M.B., Calvo A., Gomez-Reino J.J., Siri D.A., Tomsic M., Alecock E., Woodworth T., Genovese M.C.: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis., 2010; 69: 88–96 JonesG. SebbaA. GuJ. LowensteinM.B. CalvoA. Gomez-ReinoJ.J. SiriD.A. TomsicM. AlecockE. WoodworthT. GenoveseM.C. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Ann. Rheum. Dis. 2010 69 88 96 10.1136/ard.2008.105197374751919297346 Search in Google Scholar

[36] Kulnigg S., Gasche C.: Systematic review: managing anaemia in Crohn’s disease. Aliment. Pharmacol. Ther., 2006; 24: 1507–1523 KulniggS. GascheC. Systematic review: managing anaemia in Crohn’s disease Aliment. Pharmacol. Ther. 2006 24 1507 1523 10.1111/j.1365-2036.2006.03146.x17206940 Search in Google Scholar

[37] Lai Y., Dong C.: Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. Int. Immunol., 2016; 28: 181–188 LaiY. DongC. Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases Int. Immunol. 2016 28 181 188 10.1093/intimm/dxv063488987826545932 Search in Google Scholar

[38] Lankhorst C.E., Wish J.B.: Anemia in renal disease: diagnosis and management. Blood Rev., 2010; 24: 39–47 LankhorstC.E. WishJ.B. Anemia in renal disease: diagnosis and management Blood Rev. 2010 24 39 47 10.1016/j.blre.2009.09.00119833421 Search in Google Scholar

[39] Macdougall I.C., Bircher A.J., Eckardt K.U., Obrador G.T., Pollock C.A., Steinvinkel P., Swinkels D.W., Wanner C., Weiss G., Chertow G.M.: Iron management in chronic kidney disease: Conclusions from a ‘Kidney Disease: Improving Global Outcomes’ (KDIGO) Controversies Conference. Kidney Int., 2016; 89: 28–39 MacdougallI.C. BircherA.J. EckardtK.U. ObradorG.T. PollockC.A. SteinvinkelP. SwinkelsD.W. WannerC. WeissG. ChertowG.M. Iron management in chronic kidney disease: Conclusions from a ‘Kidney Disease: Improving Global Outcomes’ (KDIGO) Controversies Conference Kidney Int. 2016 89 28 39 10.1016/j.kint.2015.10.00226759045 Search in Google Scholar

[40] Macovei L.A., Brujbu I.C.: Clinical and epidemiological study on the prevalence of rheumatoid arthritis in some demographic structures. Rev. Med. Chir. Soc. Med. Nat. Iasi, 2013; 117: 747–753 MacoveiL.A. BrujbuI.C. Clinical and epidemiological study on the prevalence of rheumatoid arthritis in some demographic structures Rev. Med. Chir. Soc. Med. Nat. Iasi 2013 117 747 753 Search in Google Scholar

[41] McLean E., Cogswell M., Egli I., Wojdyla D., de Benoist B.: Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutr., 2009; 12: 444–454 McLeanE. CogswellM. EgliI. WojdylaD. de BenoistB. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005 Public Health Nutr. 2009 12 444 454 10.1017/S136898000800240118498676 Search in Google Scholar

[42] Miller J.L.: Iron deficiency anemia: a common and curable disease. Cold Spring Harb. Perspect. Med., 2013; 3: a011866 MillerJ.L. Iron deficiency anemia: a common and curable disease Cold Spring Harb. Perspect. Med. 2013 3 a011866 10.1101/cshperspect.a011866368588023613366 Search in Google Scholar

[43] Moldawer L.L., Marano M.A., Wei H., Fong Y., Silen M.L., Kuo G., Manogue K.R., Vlassara H., Cohen H., Cerami A.: Cachectin/tumor necrosis factor-α alters red blood cell kinetics and induces anemia in vivo. FASEB. J., 1989; 3: 1637–1643 MoldawerL.L. MaranoM.A. WeiH. FongY. SilenM.L. KuoG. ManogueK.R. VlassaraH. CohenH. CeramiA. Cachectin/tumor necrosis factor-α alters red blood cell kinetics and induces anemia in vivo FASEB. J. 1989 3 1637 1643 10.1096/fasebj.3.5.27841162784116 Search in Google Scholar

[44] Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., Ganz T.: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest., 2004; 113: 1271–1276 NemethE. RiveraS. GabayanV. KellerC. TaudorfS. PedersenB.K. GanzT. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin J. Clin. Invest. 2004 113 1271 1276 10.1172/JCI200420945 Search in Google Scholar

[45] Neogi T., Aletaha D., Silman A.J., Naden R.L., Felson D.T., Aggrawal L., Bingham C.O., Birnbaum N.S., Burmester G.R., Bykerk V.P., Cohen M.D., Combe B., Costenbader K.H., Dougados M., Emery P., et al.: The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum., 2010; 62: 2582–2591 NeogiT. AletahaD. SilmanA.J. NadenR.L. FelsonD.T. AggrawalL. BinghamC.O. BirnbaumN.S. BurmesterG.R. BykerkV.P. CohenM.D. CombeB. CostenbaderK.H. DougadosM. EmeryP. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report Arthritis Rheum. 2010 62 2582 2591 10.1002/art.27580307796120872596 Search in Google Scholar

[46] Ohtsuji M., Lin Q., Nishikawa K., Ohtsuji N., Okazaki H., Tsurui H., Amano H., Shirai T., Nishimoto N., Nishimura H., Hirose S., et al.: IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model. Mod. Rheumatol., 2015; 25: 270–277 OhtsujiM. LinQ. NishikawaK. OhtsujiN. OkazakiH. TsuruiH. AmanoH. ShiraiT. NishimotoN. NishimuraH. HiroseS. IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model Mod. Rheumatol. 2015 25 270 277 10.3109/14397595.2014.95003525159156 Search in Google Scholar

[47] Okada Y., Wu D., Trynka G., Raj T., Terao C., Ikari K., Kochi Y., Ohmura K., Suzuki A., Yoshida S., Graham R.R., Manoharan A., Ortmann W., Bhangale T., Denny J.C., et al.: Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature, 2014; 506: 376–381 OkadaY. WuD. TrynkaG. RajT. TeraoC. IkariK. KochiY. OhmuraK. SuzukiA. YoshidaS. GrahamR.R. ManoharanA. OrtmannW. BhangaleT. DennyJ.C. Genetics of rheumatoid arthritis contributes to biology and drug discovery Nature 2014 506 376 381 10.1038/nature12873394409824390342 Search in Google Scholar

[48] Okonko D.O., Grzeslo A., Witkowski T., Mandal A.K., Slater R.M., Roughton M., Foldes G., Thum T., Majda J., Banasiak W., Missouris C.G., Poole-Wilson P.A., Anker S.D., Ponikowski P., et al.: Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J. Am. Coll. Cardiol., 2008; 51: 103–112 OkonkoD.O. GrzesloA. WitkowskiT. MandalA.K. SlaterR.M. RoughtonM. FoldesG. ThumT. MajdaJ. BanasiakW. MissourisC.G. Poole-WilsonP.A. AnkerS.D. PonikowskiP. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial J. Am. Coll. Cardiol. 2008 51 103 112 10.1016/j.jacc.2007.09.03618191732 Search in Google Scholar

[49] Okonko D.O., Mandal A.K., Missouris C.G., Poole-Wilson P.A.: Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J. Am. Coll. Cardiol., 2011; 58: 1241–1251 OkonkoD.O. MandalA.K. MissourisC.G. Poole-WilsonP.A. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival J. Am. Coll. Cardiol. 2011 58 1241 1251 10.1016/j.jacc.2011.04.04021903058 Search in Google Scholar

[50] Onken J.E., Bregman D.B., Harrington R.A., Morris D., Buerkert J., Hamerski D., Iftikhar H., Mangoo-Karim R., Martin E.R., Martinez C.O., Newman G.E., Qunibi W.Y., Ross D.L., Singh B., Smith M.T., et al.: Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol. Dial. Transplant., 2014; 29: 833–842 OnkenJ.E. BregmanD.B. HarringtonR.A. MorrisD. BuerkertJ. HamerskiD. IftikharH. Mangoo-KarimR. MartinE.R. MartinezC.O. NewmanG.E. QunibiW.Y. RossD.L. SinghB. SmithM.T. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial Nephrol. Dial. Transplant. 2014 29 833 842 10.1093/ndt/gft25123963731 Search in Google Scholar

[51] Ponikowski P., van Veldhuisen D.J., Comin-Colet J., Ertl G., Komajda M., Mareev V., Parkhomenko A., Tavazzi L., Levesque V., Mori C., Roubert B., Filippatos G., Ruschitzka F., Anker S.D., CONFIRM-HF Investigators: Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur. Heart J., 2015; 36: 657–668 PonikowskiP. van VeldhuisenD.J. Comin-ColetJ. ErtlG. KomajdaM. MareevV. ParkhomenkoA. TavazziL. LevesqueV. MoriC. RoubertB. FilippatosG. RuschitzkaF. AnkerS.D. CONFIRM-HF Investigators Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency Eur. Heart J. 2015 36 657 668 10.1093/eurheartj/ehu385435935925176939 Search in Google Scholar

[52] Raj D.S.: Role of interleukin-6 in the anemia of chronic disease. Semin. Arthritis Rheum., 2009; 38: 382–388 RajD.S. Role of interleukin-6 in the anemia of chronic disease Semin. Arthritis Rheum. 2009 38 382 388 10.1016/j.semarthrit.2008.01.00618336871 Search in Google Scholar

[53] Reynolds G., Gibbon J.R., Pratt A.G., Wood M.J., Coady D., Raftery G., Lorenzi A.R., Gray A., Filer A., Buckley C.D., Haniffa M.A., Isaacs J.D., Hilkens C.M.: Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis. Ann. Rheum. Dis., 2016; 75: 899–907 ReynoldsG. GibbonJ.R. PrattA.G. WoodM.J. CoadyD. RafteryG. LorenziA.R. GrayA. FilerA. BuckleyC.D. HaniffaM.A. IsaacsJ.D. HilkensC.M. Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis Ann. Rheum. Dis. 2016 75 899 907 10.1136/annrheumdis-2014-206578485357625923217 Search in Google Scholar

[54] Saito H.: Metabolism of iron stores. Nagoya J. Med. Sci., 2014; 76: 235–254 SaitoH. Metabolism of iron stores Nagoya J. Med. Sci. 2014 76 235 254 Search in Google Scholar

[55] Saito H., Hayashi H., Tomita A., Ohashi H., Maeda H., Naoe T.: Increasing and decreasing phases of ferritin and hemosiderin iron determined by serum ferritin kinetics. Nagoya J. Med. Sci., 2013; 75: 213–223 SaitoH. HayashiH. TomitaA. OhashiH. MaedaH. NaoeT. Increasing and decreasing phases of ferritin and hemosiderin iron determined by serum ferritin kinetics Nagoya J. Med. Sci. 2013 75 213 223 Search in Google Scholar

[56] Selmi C., Lu Q., Humble M.C.: Heritability versus the role of the environment in autoimmunity. J. Autoimmun., 2012; 39: 249–252 SelmiC. LuQ. HumbleM.C. Heritability versus the role of the environment in autoimmunity J. Autoimmun. 2012 39 249 252 10.1016/j.jaut.2012.07.01122980030 Search in Google Scholar

[57] Selmi C., Shoenfeld Y.: Open questions in autoimmunity: discussions from the 2013 Controversies in Rheumatology and Autoimmunity Meeting. BMC Med., 2014; 12: 50 SelmiC. ShoenfeldY. Open questions in autoimmunity: discussions from the 2013 Controversies in Rheumatology and Autoimmunity Meeting BMC Med. 2014 12 50 10.1186/1741-7015-12-50398470024642104 Search in Google Scholar

[58] Shander A., Goodnough L.T., Javidroozi M., Auerbach M., Carson J., Ershler W.B., Ghiglione M., Glaspy J., Lew I.: Iron deficiency anemia – bridging the knowledge and practice gap. Transfus. Med. Rev., 2014; 28: 156–166 ShanderA. GoodnoughL.T. JavidrooziM. AuerbachM. CarsonJ. ErshlerW.B. GhiglioneM. GlaspyJ. LewI. Iron deficiency anemia – bridging the knowledge and practice gap Transfus. Med. Rev. 2014 28 156 166 10.1016/j.tmrv.2014.05.00124931617 Search in Google Scholar

[59] Siebert S., Tsoukas A., Robertson J., McInnes I.: Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol. Rev., 2015; 67: 280–309 SiebertS. TsoukasA. RobertsonJ. McInnesI. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases Pharmacol. Rev. 2015 67 280 309 10.1124/pr.114.009639 Search in Google Scholar

[60] Smyrnowa G.: The relationship between hemoglobin level and disease activity in patients with rheumatoid arthritis. Rev. Bras. Reumatol., 2014; 54: 437–440 [Article in Portuguese] SmyrnowaG. The relationship between hemoglobin level and disease activity in patients with rheumatoid arthritis Rev. Bras. Reumatol. 2014 54 437 440 [Article in Portuguese] 10.1016/j.rbre.2014.06.003 Search in Google Scholar

[61] Song S.N., Iwahashi M., Tomosugi N., Uno K., Yamana J., Yamana S., Isobe T., Ito H., Kawabata H., Yoshizaki K.: Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res. Ther., 2013; 15: R141 SongS.N. IwahashiM. TomosugiN. UnoK. YamanaJ. YamanaS. IsobeT. ItoH. KawabataH. YoshizakiK. Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients Arthritis Res. Ther. 2013 15 R141 10.1186/ar4323 Search in Google Scholar

[62] Stancu S., Stanciu A., Zugravu A., Barsan L., Dumitry D., Lipan M., Mircescu G.: Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am. J. Kidney Dis., 2010; 55: 639–647 StancuS. StanciuA. ZugravuA. BarsanL. DumitryD. LipanM. MircescuG. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD Am. J. Kidney Dis. 2010 55 639 647 10.1053/j.ajkd.2009.10.043 Search in Google Scholar

[63] Stein J., Bager P., Befrits R., Danese S., Gasche C., Lerebours E.: Current practice of anemia management in patients with inflammatory bowel disease across four European countries. Gastroenterology, 2011; 140: S556 SteinJ. BagerP. BefritsR. DaneseS. GascheC. LereboursE. Current practice of anemia management in patients with inflammatory bowel disease across four European countries Gastroenterology 2011 140 S556 10.1016/S0016-5085(11)62303-2 Search in Google Scholar

[64] Sudol-Szopinska I., Kontny E., Maslinski W., Prochorec-Sobieszek M., Warczynska A., Kwiatkowska B.: Significance of bone marrow edema in pathogenesis of rheumatoid arthritis. Pol. J. Radiol., 2013; 78: 57–63 Sudol-SzopinskaI. KontnyE. MaslinskiW. Prochorec-SobieszekM. WarczynskaA. KwiatkowskaB. Significance of bone marrow edema in pathogenesis of rheumatoid arthritis Pol. J. Radiol. 2013 78 57 63 10.12659/PJR.883768359614623493495 Search in Google Scholar

[65] Susantitaphong P., Alqahtani F., Jaber B.L.: Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: A meta-analysis. Am. J. Nephrol., 2014; 39: 130–141 SusantitaphongP. AlqahtaniF. JaberB.L. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: A meta-analysis Am. J. Nephrol. 2014 39 130 141 10.1159/00035833624513913 Search in Google Scholar

[66] Sy T., Jamal M.M.: Epidemiology of hepatitis C virus (HCV) infection. Int. J. Med. Sci., 2006; 3: 41–46 SyT. JamalM.M. Epidemiology of hepatitis C virus (HCV) infection Int. J. Med. Sci. 2006 3 41 46 10.7150/ijms.3.41141584416614741 Search in Google Scholar

[67] Theurl I., Aigner E., Theurl M., Nairz M., Seifert M., Schroll A., Sonnweber T., Eberwein L., Witcher D.R., Murphy A.T., Wroblewski V.J., Wurz E., Datz C., Weiss G.: Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: Diagnostic and therapeutic implications. Blood, 2009; 113: 5277–5286 TheurlI. AignerE. TheurlM. NairzM. SeifertM. SchrollA. SonnweberT. EberweinL. WitcherD.R. MurphyA.T. WroblewskiV.J. WurzE. DatzC. WeissG. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: Diagnostic and therapeutic implications Blood 2009 113 5277 5286 10.1182/blood-2008-12-19565119293425 Search in Google Scholar

[68] Tobon G.J., Youinou P., Saraux A.: The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis. J. Autoimmun., 2010; 35: 10–14 TobonG.J. YouinouP. SarauxA. The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis J. Autoimmun. 2010 35 10 14 10.1016/j.jaut.2009.12.00920080387 Search in Google Scholar

[69] Voulgari P.V., Kolios G., Papadopulos G.K., Katsaraki A., Seferiadis K., Drosos A.A.: Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin. Immunol., 1999; 92: 153–160 VoulgariP.V. KoliosG. PapadopulosG.K. KatsarakiA. SeferiadisK. DrososA.A. Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis Clin. Immunol. 1999 92 153 160 10.1006/clim.1999.4736 Search in Google Scholar

[70] Weiss G., Goodnough L.T.: Anemia of chronic disease. N. Engl. J. Med., 2005; 352: 1011–1023 WeissG. GoodnoughL.T. Anemia of chronic disease N. Engl. J. Med. 2005 352 1011 1023 10.1201/b14192 Search in Google Scholar

[71] Wetmore J.B., Peng Y., Jackson S., Malton T.J., Collins A.J., Gilbertson D.T.: Patient characteristics, disease burden, and medication use in stage 4–5 chronic kidney disease patients. Clin. Nephrol., 2016; 85: 101–111 WetmoreJ.B. PengY. JacksonS. MaltonT.J. CollinsA.J. GilbertsonD.T. Patient characteristics, disease burden, and medication use in stage 4–5 chronic kidney disease patients Clin. Nephrol. 2016 85 101 111 10.5414/CN108626 Search in Google Scholar

[72] Wilson A., Yu H.T., Goodnough L.T., Nissenson A.R.: Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am. J. Med., 2004; 116: 50S–57S WilsonA. YuH.T. GoodnoughL.T. NissensonA.R. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature Am. J. Med. 2004 116 50S 57S 10.1016/j.amjmed.2003.12.012 Search in Google Scholar

[73] Wish J.B.: Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin. J. Am. Soc. Nephrol., 2006; 1 (Suppl.): S4–S8 WishJ.B. Assessing iron status: Beyond serum ferritin and transferrin saturation Clin. J. Am. Soc. Nephrol. 2006 1 Suppl. S4 S8 10.2215/CJN.01490506 Search in Google Scholar

[74] Zimmermann M.B., Hurrell R.F.: Nutritional iron deficiency. Lancet, 2007; 370: 511–520 ZimmermannM.B. HurrellR.F. Nutritional iron deficiency Lancet 2007 370 511 520 10.1016/S0140-6736(07)61235-5 Search in Google Scholar